我如何监测慢性髓性白血病中的残留疾病。
How I monitor residual disease in chronic myeloid leukemia.
作者信息
Radich Jerald P
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
出版信息
Blood. 2009 Oct 15;114(16):3376-81. doi: 10.1182/blood-2009-02-163485. Epub 2009 Aug 6.
Abstract
Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and "guidelines" using the molecular endpoints of CML has outpaced practice norms, commercial laboratory application, and reimbursement practices, leaving some anxiety (if not confusion and despair) about molecular monitoring in the day-to-day treatment of CML. This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic.
摘要
慢性髓性白血病（CML）的分子监测是记录治疗反应和预测复发的有力工具。尽管如此，使用CML分子终点的临床试验和“指南”的激增已经超过了实践规范、商业实验室应用和报销实践，这使得在CML的日常治疗中对分子监测产生了一些焦虑（如果不是困惑和绝望的话）。本文将试图通过描述我如何监测CML来解决这些问题，简而言之，就是保持关注且不恐慌。
相似文献
1
How I monitor residual disease in chronic myeloid leukemia.我如何监测慢性髓性白血病中的残留疾病。
Blood. 2009 Oct 15;114(16):3376-81. doi: 10.1182/blood-2009-02-163485. Epub 2009 Aug 6.
2
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.血浆RNA作为慢性髓性白血病患者分子反应监测中替代细胞的手段。
Haematologica. 2007 Feb;92(2):170-5. doi: 10.3324/haematol.10360.
3
A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.一种新的高灵敏度实时定量 PCR 方法，用于检测 BCR-ABL1，以监测伊马替尼停药后慢性髓性白血病的微小残留病。
PLoS One. 2019 Mar 5;14(3):e0207170. doi: 10.1371/journal.pone.0207170. eCollection 2019.
4
Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.定量实时聚合酶链反应作为检测摩洛哥慢性髓性白血病患者微小残留病的有效分子工具。
Genet Mol Res. 2015 Feb 6;14(1):1044-55. doi: 10.4238/2015.February.6.8.
5
Treatment and molecular monitoring update in chronic myeloid leukemia management.慢性髓性白血病管理中的治疗与分子监测进展
Ann Biol Clin (Paris). 2017 Apr 1;75(2):129-145. doi: 10.1684/abc.2017.1233.
6
Monitoring your patients with chronic myeloid leukemia.
Am J Health Syst Pharm. 2006 Dec 1;63(23 Suppl 8):S5-9; quiz S21-2. doi: 10.2146/ajhp060524.
7
Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.异基因骨髓移植后慢性髓性白血病患者治疗决策的分子基础。
Haematologica. 2000 Oct;85(10):1072-82.
8
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.慢性髓性白血病治疗期间分子监测的价值：一项癌症与白血病B组研究
J Clin Oncol. 1997 Jan;15(1):26-36. doi: 10.1200/JCO.1997.15.1.26.
9
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
Br J Haematol. 1999 Dec;107(3):587-99. doi: 10.1046/j.1365-2141.1999.01749.x.
引用本文的文献
1
Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma.通过动态反应评估方法重新定义血液系统恶性肿瘤的预后：慢性粒细胞白血病、霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤和多发性骨髓瘤的经验教训
Indian J Hematol Blood Transfus. 2020 Jul;36(3):447-457. doi: 10.1007/s12288-019-01213-7. Epub 2019 Oct 22.
2
Prognostication with circulating tumor DNA: is it ready for prime time?循环肿瘤 DNA 预测：是否已准备好成为主流？
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):47-52. doi: 10.1182/hematology.2019000013.
3
Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study.应用液滴数字聚合酶链反应检测微小残留病：一项前瞻性多机构研究。
In Vivo. 2019 Nov-Dec;33(6):2273-2280. doi: 10.21873/invivo.11733.
4
Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies.结构变异作为血液系统恶性肿瘤靶向治疗的基础
Front Oncol. 2019 Aug 28;9:839. doi: 10.3389/fonc.2019.00839. eCollection 2019.
5
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.Blinatumomab 治疗 B 细胞前体急性淋巴细胞白血病成人患者的微小残留病。
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
6
Towards Stratified Medicine in Plasma Cell Myeloma.迈向浆细胞骨髓瘤的分层医学
Int J Mol Sci. 2016 Oct 21;17(10):1760. doi: 10.3390/ijms17101760.
7
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代慢性髓性白血病中3q26.2及其他3号染色体异常的临床及预后意义
Blood. 2015 Oct 1;126(14):1699-706. doi: 10.1182/blood-2015-05-646489. Epub 2015 Aug 4.
8
Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.基因组定量实时PCR证实，在慢性髓性白血病中，超过30%基于mRNA的定量逆转录PCR结果为阴性的样本存在残留病阳性。
Oncoscience. 2014 Jul 23;1(7):510-21. doi: 10.18632/oncoscience.65. eCollection 2014.
9
Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.多发性骨髓瘤微小残留病评估中的争议：使用高灵敏度技术检测微小残留病阴性的临床意义
Curr Hematol Malig Rep. 2014 Dec;9(4):368-78. doi: 10.1007/s11899-014-0237-y.
10
Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.慢性髓性白血病中分子监测结果的解读及国际标准化
J Adv Pract Oncol. 2012 May;3(3):151-60. doi: 10.6004/jadpro.2012.3.3.3.
本文引用的文献
1
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.在国际报告范围内进行BCR-ABL测量所需的性能特征，以便对个体患者的反应进行一致的解读，并比较临床试验之间的反应率。
Blood. 2008 Oct 15;112(8):3330-8. doi: 10.1182/blood-2008-04-150680. Epub 2008 Aug 6.
2
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.在对伊马替尼有反应的慢性期慢性髓性白血病患者中发现激酶结构域突变，可能会识别出疾病进展风险高的患者。
J Clin Oncol. 2008 Oct 10;26(29):4806-13. doi: 10.1200/JCO.2008.16.9953. Epub 2008 Jul 21.
3
Monitoring treatment of chronic myeloid leukemia.监测慢性髓性白血病的治疗。
Haematologica. 2008 Feb;93(2):161-9. doi: 10.3324/haematol.12588.
4
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.在BCR-ABL酪氨酸激酶抑制剂的现代时代监测慢性髓性白血病的反应和病程：关于监测方法使用和解读的实用建议
Blood. 2008 Feb 15;111(4):1774-80. doi: 10.1182/blood-2007-09-110189. Epub 2007 Nov 30.
5
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.伊马替尼治疗失败后接受达沙替尼治疗的慢性粒细胞白血病患者激酶结构域突变的体内动力学
Blood. 2008 Feb 15;111(4):2378-81. doi: 10.1182/blood-2007-06-096396. Epub 2007 Nov 2.
6
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.在接受伊马替尼治疗获得完全细胞遗传学缓解的慢性髓性白血病患者中，BCR-ABL RNA水平升高半对数预示着更高的复发风险。
Clin Cancer Res. 2007 Oct 15;13(20):6136-43. doi: 10.1158/1078-0432.CCR-07-1112.
7
Chronic myelogenous leukemia.慢性粒细胞白血病
J Natl Compr Canc Netw. 2007 May;5(5):474-96. doi: 10.6004/jnccn.2007.0043.
8
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.在对伊马替尼产生稳定完全细胞遗传学反应的少数患者中，BCR-ABL激酶结构域发生突变。
Leukemia. 2007 Mar;21(3):489-93. doi: 10.1038/sj.leu.2404554. Epub 2007 Jan 25.
9
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.接受伊马替尼治疗的慢性髓性白血病患者的五年随访
N Engl J Med. 2006 Dec 7;355(23):2408-17. doi: 10.1056/NEJMoa062867.
10
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.关于统一慢性髓性白血病患者BCR-ABL转录本检测现行方法的建议依据。
Leukemia. 2006 Nov;20(11):1925-30. doi: 10.1038/sj.leu.2404388. Epub 2006 Sep 14.
Zotero 插件